Skip to main content
SpringerLink
Log in

Clinical Studies of Thrombopoietin

  • Chapter
Clinical Applications of Cytokines and Growth Factors

Part of the book series: Developments in Oncology ((DION,volume 80))

  • 111 Accesses

Abstract

It was recognized soon after the discovery of the ligand to c-mpl that this was the long sought after central regulator of megakaryocytopoiesis and thrombopoiesis 1. The native or biological form of Mpl ligand is referred to as thrombopoietin (TPO). Two formulations of Mpl ligand are in clinical development. Recombinant human megakaryocyte growth and development factor (rHu-MGDF) is a truncated form of Mpl ligand with identical biological activity. Pegylation of MGDF, in which it is coupled to poly-ethylene glycol to form PEG-rHuMGDF, results in a molecule that is approximately ten times more potent in vivo than non-pegylated MGDF 2. PEG-rHuMGDF has been chosen as the agent for clinical use. A full length gycosylated form of thrombopoietin, recombinant human TPO (rTPO), is also being developed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kaushansky K Thrombopoietin: The primary regulator of platelet production. Blood 86: 419–31, 1995.

    PubMed  CAS  Google Scholar 

  2. Vilmer E, Guglielmi P, David V, et al. Predominant expression of circulating CD3+ lymphocytes bearing gamma T cell receptor in a prolonged immunodeficiency after allogeneic bone marrow transplantation. J.Clin.Invest. 82: 755–61, 1988.

    Article  PubMed  CAS  Google Scholar 

  3. Basser RL, Rasko JEJ, Clarke K, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 348: 1279–81, 1996.

    Article  PubMed  CAS  Google Scholar 

  4. O’Malley CJ, Rasko JEJ, Basser RL, et al. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood 88: 3288–98, 1996.

    PubMed  Google Scholar 

  5. Rasko JEJ, Basser RL, Boyd J, et al. Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDF. Br J Haematol 97: 871–80, 1997.

    Article  PubMed  CAS  Google Scholar 

  6. Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N.Engl.J.Med. 336: 404–9, 1997.

    Article  PubMed  CAS  Google Scholar 

  7. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 126: 673–81, 1997.

    PubMed  CAS  Google Scholar 

  8. Kuter D, McCullough J, Romo J, et al. Treatment of platelet (PLT) donors with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increases circulating PLT counts (CTS) and PLT apheresis yields and increases platelet incremements in recipients of PLT tranftisions. Blood 90 (suppl 1): 579a (Abstract), 1997.

    Google Scholar 

  9. Basser RL, Rasko JEJ, Clarke K, et al. Randomised, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 89: 3118–28, 1997.

    PubMed  CAS  Google Scholar 

  10. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N.Engl.J.Med. 325: 164–70, 1997.

    Article  Google Scholar 

  11. Szer J, Basser R, Underhill C, et al. Reduction of thrombocytopenia (TCP) after multicycle, intensive chemotherapy by megakaryocyte growth and development factor (PEG-rHuMGDF). Pro Am Soc Clin Oncol 17: 76a (Abstract), 1998.

    Google Scholar 

  12. Moskowitz C, Nimer S, Gabrilove J, et al. A randomized, double-blind, placebo-controlled, dose-finding, efficacy and safety study of PEG-rHuMGDF (M) in non-Hodgkin’s lymphoma (NHL) patients (pts) treated with ICE (ifosfamide, carboplatin and etoposide). Pro Am Soc Clin Oncol 17: 76a (Abstract), 1998.

    Google Scholar 

  13. Crawford J, Glaspy J, Belani C, et al. A randomized, placebo-controlled, blinded, dose scheduling trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHMGDF) with filgrastim support in non-small cell lung cancer (NSCLC) patients treated with paclitaxel and carboplatin during multiple cycles of chemotherapy. Pro Am Soc Clin Oncol 17: 73a (Abstract), 1998.

    Google Scholar 

  14. Vadhan-Raj S, Verschraegen C, McGarry L, et al. Recombinant human thrombopoietin (rhTPO) attenuates high-dose carboplatin (C)-induced thrombocytopenia in patients with gynecologic malignancy. Blood 90 (suppl 1): 580a (Abstract), 1997.

    Google Scholar 

  15. Beveridge R, Schuster M, Waller E, et al. Randomized, double-blind, placebo-controlled trial of pegylated recombinant human growth and development factor (PEG-rHUMGDF) in breast cancer patients (Pts) following autologous bone marrow transplantation (ABMT). Blood 90 (suppl 1): 580a (Abstract), 1997.

    Google Scholar 

  16. Glaspy J, Vredenburgh J, Demetri GD, et al. Effects of PEGylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) before high-dose chemotherapy (HDC) with peripheral blood progenitor cell (PBPC) support. Blood 90 (Suppl 1): 580a (Abstract), 1997.

    Google Scholar 

  17. Ginsburg AD. Platelet function in patients with high platelet counts. Ann.Intern.Med. 82: 506–11, 1975.

    PubMed  CAS  Google Scholar 

  18. Buss DH, Cashell AW, O’Connor ML, et al. Occurrence, etiology, and clinical significance of extreme thrombocytosis. Am.J.Med. 96: 247–53, 1994.

    Article  PubMed  CAS  Google Scholar 

  19. Kaushansky K, Lin N, Grossmann A, Humes J, et al. Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice. Exp.Hematol. 24: 265–69, 1996.

    PubMed  CAS  Google Scholar 

  20. Duhrsen U, Villeval JL, Boyd J, et al. Effects of recombinant granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 72: 2074–81, 1988.

    PubMed  CAS  Google Scholar 

  21. Murray LJ, Luens KM, Estrada ME, et al. Thrombopoietin mobilizes CD34+ cell subsets into peripheral blood and expands multilineage progenitors in bone marrow of cancer patients with normal hematopoiesis. Exp.Hematol. 26: 207–16, 1998.

    PubMed  CAS  Google Scholar 

  22. Bunn PA, Jr., Ridgway EC. Paraneoplastic syndromes, in Cancer: Principles and Practice of Oncology (DeVita V.T., Jr., Hellman S. & Rosenberg S.A., eds.), J.B.Lippincott Co., Philadelphia, pp. 2026–71, 1993.

    Google Scholar 

Download references

Authors
  1. Russell L. Basser
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Bone Marrow Transplant Program, Division of Hematology/Oncology, University of Florida College of Medicine, Shands Hospital, Gainesville, FL, 32610, USA

    John R. Wingard M.D. (Professor of Medicine, Director) (Professor of Medicine, Director)

  2. Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, 02115, USA

    George D. Demetri M.D. (Assistant Professor of Medicine) (Assistant Professor of Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Basser, R.L. (1999). Clinical Studies of Thrombopoietin. In: Wingard, J.R., Demetri, G.D. (eds) Clinical Applications of Cytokines and Growth Factors. Developments in Oncology, vol 80. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5013-6_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5013-6_14

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7277-6

  • Online ISBN: 978-1-4615-5013-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation